Navigation Links
GLP Preclinical Studies Demonstrate nContact Ablation Lesions Are Complete and Transmural
Date:1/25/2013

MORRISVILLE, N.C., Jan. 25, 2013 /PRNewswire/ -- Innovations In Cardiac Rhythm Management published an article by Dr. H. Edward Garrett, Jr. , MD of Baptist Memorial Hospital, Memphis, TN that evaluated nContact's unipolar epicardial ablation devices, the Numeris® and EPi-Sense® Coagulation Systems with VisiTrax®. The study purpose was to measure the ability of the device to create transmural epicardial lesions. During two chronic GLP preclinical studies performed at two sites, Saint Joseph's Translational Research Institute in Atlanta, and Integra, a USDA registered facility in Minneapolis, Minnesota, the coagulation systems produced effective epicardial ablation lesions on a beating heart that were consistently transmural in the atria and measured 7mm in depth.

Though the Company has performed thousands of ablation procedures on humans with its coagulation system involving both surgeons and EPs utilizing diagnostic and mapping technologies to assure lesion transmurality and area isolation, the paper reaffirms the science behind the technology. "The Company has always maintained that the primary weakness of other RF technologies was not maintaining consistent tissue contact on a beating heart. By integrating suction into the nContact device, it allowed consistent tissue contact and energy transmission across the ablation device which has resulted in complete long linear lesions. The conclusion of the new studies confirmed what the initial Company studies had shown," stated Dr. H. Edward Garrett, Jr. , Professor of Cardiothoracic Surgery at the University of Tennessee, Memphis.

Dr. Garrett continued, "To the Company's credit, the studies were performed under the rigorous standards of GLP and utilization of histology. Histology studies demonstrated that acute studies utilizing TTC staining may not provide an accurate and objective conclusion to the question of lesion depth. The studies demonstrated that unipolar RF energy, when in consistent tissue contact, can safely create complete lesions, and coagulate to a consistent depth. In a larger context, lesion consistency and transmurality are considered key elements to ablation success, and this study has gone a long way to explaining the superior results obtained over other ablation technologies at my institution."

About nContact, Inc.
nContact, Inc. is the leading innovator in epicardial ablation devices and techniques. Its mission is to transform the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias.

Its lead technologies, the EPi-Sense® and Numeris® Coagulation Systems with VisiTrax®, have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

The EPi-Sense® and Numeris® Coagulation Systems with VisiTrax® are indicated for endoscopic coagulation of cardiac tissue in the United States. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, U.S.A.

Contact:
919-655-1566
brose@ncontactinc.com

PRLog ID: www.prlog.org/12065488


'/>"/>
SOURCE nContact
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
2. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
3. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
4. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
5. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
6. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
7. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
8. Accelrys ELN Advances Innovation Lifecycle Management with Enhanced Biology Capabilities from Screening to Preclinical Development
9. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
10. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
11. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):